Cointime update: Pfizer said China’s National Medical Products Administration approved a new indication for its hemophilia therapy Beqvez (fidanacogene elaparvovec), a once-weekly fixed-dose subcutaneous non-factor treatment. The approval covers routine prophylaxis for patients aged 12 and older weighing at least 35 kg with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors, to prevent bleeding or reduce bleeding frequency.
Pfizer’s Hemophilia Drug Approved in China for New Indication
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
38m ago
Dollar Holds Near 19-Month High on Fed Rate Hike Expectations
3h ago
Iran military says it struck US drone and missile facilities at Kuwait’s Ali Al Salem base
3h ago
MARA Sells 1,713.9 BTC for $121M; BOJ Signals More Rate Hikes
4h ago
BOJ’s Ueda Says Rate Hikes Should Continue to Anchor Inflation
4h ago
South Korea’s KOSPI Turns Negative After Earlier Gaining Over 3%
5h ago
Spot silver falls 2.00% intraday to $46.44/oz, lowest since Sept 29, 2025